Subject-Specific Tumor Inhibiting Cells and the Use Thereof
AssigneesEZY Biotech LLC, Adaerata, Limited Partnership
InventorsHUA GU, Gang G Xu, Adeline Gadzinski, Haijun Tong
Life of this patent
Estimating the term…
Loading patent…
AssigneesEZY Biotech LLC, Adaerata, Limited Partnership
InventorsHUA GU, Gang G Xu, Adeline Gadzinski, Haijun Tong
Estimating the term…
This disclosure is directed to a pharmaceutical composition comprises tumor inhibiting cells (TICs) and a method for producing the TICs. The tumor inhibiting cells can be derived from immune cells including T cells, NK cells, or a combination thereof, modified to have inactivated Cbl-b gene alleles and free from Cbl-b bio-function (Cbl-b−/− TICs). The Cbl-b−/− TICs are free from deoxyribonucleic acids exogenous to the immune cells. The immune cells can be isolated using a portable cell isolation and modification device. This disclosure is further directed to a method for treating tumorous conditions in subjects. The pharmaceutical composition can provide a subject-specific tumor treatment.
A pharmaceutical composition comprising a population of Cbl-b−/− tumor inhibiting cells (Cbl-b−/− TICs) modified from immune cells, wherein the Cbl-b−/− TICs have inactivated Cbl-b genomic alleles and are free from Cbl-b bio-function, and wherein the Cbl-b−/− TICS are free from deoxyribonucleic acids exogenous to the immune cells and free from viral nucleic acids exogenous to the immune cells.
(canceled)
(canceled)
A method for producing Cbl-b−/− tumor inhibiting cells (TICs), the method comprising the steps of:
(canceled)
(canceled)
(canceled)
A method for treating a tumorous condition of a subject in need thereof, the method comprising the steps of:
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
31-62. (canceled)
Dependencies are inferred from the claim text.